| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
31,804,000 |
| Market
Cap: |
630.67(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.85 - $26.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 609 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile AnaptysBio is a clinical stage biotechnology company developing immunology therapeutic product candidates focused on immune control mechanisms applicable to inflammation and immuno-oncology indications. Co.'s wholly-owned antibody programs include: imsidolimab, which inhibits the interleukin-36 receptor and is being developed for the treatment of multiple dermatological inflammatory diseases; rosnilimab, which is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling via rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, which is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
668,237 |
| Total Buy Value |
$0 |
$0 |
$0 |
$14,453,966 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
157,005 |
171,792 |
185,897 |
858,303 |
| Total Sell Value |
$3,586,878 |
$3,902,662 |
$4,176,146 |
$18,726,680 |
| Total People Sold |
3 |
4 |
4 |
5 |
| Total Sell Transactions |
4 |
9 |
14 |
18 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Suria Hamza |
President, CEO |
• • – |
2021-05-12 |
4 |
OE |
$1.12 |
$11,200 |
D/D |
10,000 |
57,636 |
|
- |
|
| Nodelman Oleg |
Director |
– • • |
2021-05-04 |
4 |
B |
$23.25 |
$3,835,755 |
I/I |
165,000 |
7,520,424 |
2.25 |
11% |
|
| Nodelman Oleg |
Director |
– • • |
2021-05-03 |
4 |
B |
$23.31 |
$484,873 |
I/I |
20,800 |
7,355,424 |
2.25 |
9% |
|
| Nodelman Oleg |
Director |
– • • |
2021-04-30 |
4 |
B |
$23.16 |
$826,816 |
I/I |
35,700 |
7,334,624 |
2.25 |
12% |
|
| Nodelman Oleg |
Director |
– • • |
2021-04-27 |
4 |
B |
$23.82 |
$805,089 |
I/I |
33,800 |
7,298,924 |
2.25 |
12% |
|
| Nodelman Oleg |
Director |
– • • |
2021-04-26 |
4 |
B |
$23.80 |
$330,859 |
I/I |
13,900 |
7,265,124 |
2.25 |
9% |
|
| Nodelman Oleg |
Director |
– • • |
2021-04-23 |
4 |
B |
$23.54 |
$2,344,285 |
I/I |
99,600 |
7,251,224 |
2.25 |
10% |
|
| Nodelman Oleg |
Director |
– • • |
2021-04-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,151,624 |
|
14% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2021-03-09 |
4 |
B |
$18.70 |
$9,928,426 |
I/I |
531,000 |
7,151,624 |
1.5 |
32% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2021-03-08 |
4 |
B |
$18.97 |
$52,694,310 |
I/I |
2,777,800 |
6,620,624 |
1.5 |
34% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2021-02-23 |
4 |
B |
$25.48 |
$751,657 |
I/I |
29,500 |
3,842,824 |
1.5 |
-3% |
|
| Loumeau Eric J |
COO, General Counsel |
• – – |
2021-02-12 |
4 |
S |
$35.00 |
$350,000 |
D/D |
(10,000) |
0 |
|
29% |
|
| Loumeau Eric J |
COO, General Counsel |
• – – |
2021-02-12 |
4 |
OE |
$14.02 |
$140,200 |
D/D |
10,000 |
10,000 |
|
- |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2021-01-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,813,324 |
|
11% |
|
| Topper James N |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
48,958 |
80,812 |
|
- |
|
| Topper James N |
Director |
– • – |
2020-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,416,747) |
199,529 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2020-03-10 |
4 |
OE |
$1.12 |
$11,200 |
D/D |
10,000 |
47,636 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2020-02-05 |
4 |
OE |
$1.12 |
$11,200 |
D/D |
10,000 |
37,636 |
|
- |
|
| Ware J. Anthony |
Director |
– • – |
2019-12-10 |
4 |
B |
$14.05 |
$50,580 |
D/D |
3,600 |
3,600 |
2.39 |
- |
|
| Londei Marco |
Chief Medical Officer |
• – – |
2019-11-27 |
4 |
OE |
$6.93 |
$320,180 |
D/D |
46,202 |
68,579 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2019-11-22 |
4 |
OE |
$1.12 |
$11,200 |
D/D |
10,000 |
27,636 |
|
- |
|
21 Records found
|
1
|
Page 1 of 1 |
|
|
1.51 (7.08%) 
